Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...